ANI Pharmaceuticals is executing a successful transformation toward high-margin rare disease products, with revenue accelerating 43.8% year-over-year in 2026Q2 and gross margins expanding to 62.4%. The company has deleveraged aggressively, cutting total debt f...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 7, 2026 | $2.21+8.3% vs $2.04 | $266M+2.3% vs $260M |
Q2 2026 May 8, 2026 | $2.05+60.2% vs $1.28 | $237M+14.4% vs $208M |
Q1 2026 Feb 27, 2026 | $2.33+17.1% vs $1.99 | $247M+6.9% vs $231M |
Q4 2025 Nov 7, 2025 | $2.04+17.2% vs $1.74 | $228M-1.9% vs $232M |
ANI Pharmaceuticals, Inc. (ANIP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Cumberland Pharmaceuticals (NASDAQ: CPIX - Get Free Report) and ANI Pharmaceuticals (NASDAQ: ANIP - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation. Analyst Ratings This is a breakdown of
PRINCETON, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company's executive leadership team, will participate in fireside chats at the following upcoming investor conferences:
– Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company – PRINCETON, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today reported the addition of Henry Gosebruch to its Board of Directors effective August 19, 2026.
Benchmark ANIP against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for ANI Pharmaceuticals, Inc. (ANIP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $77.91 | $1.77B | 23.47 | 43.78% | 8.87% | 16.16% | 0.07% | |
| $19.50 | $6.23B | 88.64 | 8.05% | 5.05% | — | — | |
| $100.00 | $6.51B | 29.33 | 0.5% | 17.69% | 23.27% | — | |
| $14.31 | $1.98B | -1.39 | -2.75% | -41.85% | -55.97% | — | |
| $35.15 | $1.42B | 29.54 | 27.37% | 6.57% | 28.67% | — | |
| $43.75 | $2.54B | -64.34 | 8.63% | -13.23% | -10.42% | — |
ANI Pharmaceuticals, Inc. (ANIP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
ANI Pharmaceuticals, Inc. (ANIP) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 7, 2026·SEC
May 21, 2026·SEC
May 13, 2026·SEC
Get notified when ANIP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ANI Pharmaceuticals, Inc. (ANIP) stock FAQ — growth, dividends, profitability & financials explained
ANI Pharmaceuticals, Inc. (ANIP) reported $978.4M in revenue for fiscal year 2025. This represents a 794936% increase from $0.1M in 1998.
ANI Pharmaceuticals, Inc. (ANIP) grew revenue by 43.8% over the past year. This is strong growth.
Yes, ANI Pharmaceuticals, Inc. (ANIP) is profitable, generating $105.8M in net income for fiscal year 2025 (8.9% net margin).
ANI Pharmaceuticals, Inc. (ANIP) does not currently pay a meaningful dividend. The company may be reinvesting profits for growth.
ANI Pharmaceuticals, Inc. (ANIP) has a return on equity (ROE) of 16.2%. This is reasonable for most industries.
ANI Pharmaceuticals, Inc. (ANIP) generated $159.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
